Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.38 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469678 | 0.89 | PTGDR2 (0.41) | ARPTGDR2MAPTPPARGSMN1; SMN2 | |
| SCHEMBL6469535 | 0.81 | AR (0.76) | ARMAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6469599 | 0.77 | ACLY (0.40) | ARPTGDR2MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL31686351 | 0.77 | PTGDR2 (0.44) | PTGDR2MAPTPPARGSMN1; SMN2 | |
| SCHEMBL6466989 | 0.76 | AR (0.67) | ARPTGDR2MAPTLMNABDKRB1 | |
| SCHEMBL6469782 | 0.76 | AR (0.74) | ARMAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6466685 | 0.75 | AR (0.59) | ARPTGDR2MAPTALDH1A1LMNA | |
| SCHEMBL6466009 | 0.74 | AR (0.83) | ARMAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6467848 | 0.73 | AR (0.66) | ARMAPTTP53ALDH1A1 | |
| SCHEMBL6466466 | 0.73 | KCNK3 (0.46) | ARMAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1466902-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | AR 6/4885PTGDR2 150/4885MAPT 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.